-
2
-
-
42649145828
-
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
-
Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193-205 (2008).
-
(2008)
Cancer Treat. Rev.
, vol.34
, pp. 193-205
-
-
Gupta, K.1
Miller, J.D.2
Li, J.Z.3
Russell, M.W.4
Charbonneau, C.5
-
4
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
DOI 10.1056/NEJMoa065044
-
Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
5
-
-
33644833910
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
-
DOI 10.1200/JCO.2005.02.2574
-
Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006). (Pubitemid 46630489)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 16-24
-
-
Motzer, R.J.1
Michaelson, M.D.2
Redman, B.G.3
Hudes, G.R.4
Wilding, G.5
Figlin, R.A.6
Ginsberg, M.S.7
Kim, S.T.8
Baum, C.M.9
DePrimo, S.E.10
Li, J.Z.11
Bello, C.L.12
Theuer, C.P.13
George, D.J.14
Rini, B.I.15
-
6
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
DOI 10.1001/jama.295.21.2516
-
Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006). (Pubitemid 43854967)
-
(2006)
Journal of the American Medical Association
, vol.295
, Issue.21
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
Curti, B.D.4
George, D.J.5
Hudes, G.R.6
Redman, B.G.7
Margolin, K.A.8
Merchan, J.R.9
Wilding, G.10
Ginsberg, M.S.11
Bacik, J.12
Kim, S.T.13
Baum, C.M.14
Michaelson, M.D.15
-
7
-
-
35148857486
-
Sunitinib efficacy against advanced renal cell carcinoma
-
DOI 10.1016/j.juro.2007.07.030, PII S0022534707017661
-
Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883-1887 (2007). (Pubitemid 47538608)
-
(2007)
Journal of Urology
, vol.178
, Issue.5
, pp. 1883-1887
-
-
Motzer, R.J.1
Michaelson, M.D.2
Rosenberg, J.3
Bukowski, R.M.4
Curti, B.D.5
George, D.J.6
Hudes, G.R.7
Redman, B.G.8
Margolin, K.A.9
Wilding, G.10
-
8
-
-
68949145218
-
Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
9
-
-
77949429364
-
Sunitinib for the management of advanced renal cell carcinoma
-
Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 10(3), 305-317 (2010).
-
(2010)
Expert Rev. Anticancer Ther
, vol.10
, Issue.3
, pp. 305-317
-
-
Escudier, B.1
-
10
-
-
66549108544
-
Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
-
Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20 (Suppl. 4), iv81-iv82 (2009).
-
(2009)
Ann. Oncol.
, vol.20
, Issue.SUPPL. 4
-
-
Escudier, B.1
Kataja, V.2
-
11
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo controlled Phase III trial
-
Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo controlled Phase III trial. Lancet 372, 449-456 (2008).
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
12
-
-
77951582589
-
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: A review of health economic evaluations
-
Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J. Chemother. 22(2), 75-82 (2010).
-
(2010)
J. Chemother
, vol.22
, Issue.2
, pp. 75-82
-
-
Norum, J.1
Nieder, C.2
Kondo, M.3
-
13
-
-
84857104145
-
Economic evaluation of sunitinib vs. interferon-A (IFN-a) in first-line metastatic renal cell carcinoma (mRCC
-
Négrier S, Remák E, Brown Rl, Kim ST, Charbonneau C, Motzer RJ. Economic evaluation of sunitinib vs. interferon-a (IFN-a) in first-line metastatic renal cell carcinoma (mRCC). Eur. J. Cancer 5(Suppl. 4), 303 (2007).
-
(2007)
Eur. J. Cancer
, vol.5
, Issue.SUPPL. 4
, pp. 303
-
-
Négrier, S.1
Remák, E.2
Rl, B.3
Kim, S.T.4
Charbonneau, C.5
Motzer, R.J.6
-
14
-
-
75349102521
-
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation
-
Thompson Coon J, Hoyle M, Green C et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol. Assess. 14 (2), 1-184 (2010).
-
(2010)
Health Technol. Assess.
, vol.14
, Issue.2
, pp. 1-184
-
-
Thompson Coon, J.1
Hoyle, M.2
Green, C.3
-
15
-
-
0031886073
-
An introduction to Markov modelling for economic evaluation
-
DOI 10.2165/00019053-199813040-00003
-
Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4), 397-409 (1998). (Pubitemid 28140699)
-
(1998)
PharmacoEconomics
, vol.13
, Issue.4
, pp. 397-409
-
-
Briggs, A.1
Sculpher, M.2
-
16
-
-
80051733969
-
Sorafenib and sunitinib in metastatic renal cell carcinoma: Cost-effectiveness analysis in reimbursement proceedings vs. data from clinical practice
-
Prague, Czech Republic, 6-9 November
-
Ondrackova B, Demlova R. Sorafenib and sunitinib in metastatic renal cell carcinoma: cost-effectiveness analysis in reimbursement proceedings vs. data from clinical practice. Presented at : ISPOR 13th Annual European Congress. Prague, Czech Republic, 6-9 November 2010.
-
(2010)
ISPOR 13th Annual European Congress
-
-
Ondrackova, B.1
Demlova, R.2
-
17
-
-
50549086998
-
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
-
Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 26(24), 3995-4000 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.24
, pp. 3995-4000
-
-
Remák, E.1
Charbonneau, C.2
Négrier, S.3
Kim, S.T.4
Motzer, R.J.5
-
18
-
-
77956373891
-
How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? the example of sunitinib for first-line treatment of metastatic renal cell carcinoma
-
Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 13(6), 837-845 (2010).
-
(2010)
Value Health
, vol.13
, Issue.6
, pp. 837-845
-
-
Chabot, I.1
Rocchi, A.2
-
19
-
-
80051746090
-
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
-
DOI: 10. 1111/j. 1464-410X.2010 (Epub ahead of print)
-
Benedict A, Figlin RA, Sandström P et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. DOI: 10. 1111/j. 1464-410X. 2010. 09957 (2011) (Epub ahead of print).
-
(2011)
BJU Int.
, pp. 09957
-
-
Benedict, A.F.1
-
20
-
-
84857101219
-
Sunitinib vs. interferon-A (IFN-a) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation
-
Remák E, Brown R, Négrier S, Motzer RJ, Kim ST, Charbonneau C. Sunitinib vs. interferon-a (IFN-a) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation. Value Health 10(6), A327-A328 (2007).
-
(2007)
Value Health
, vol.10
, Issue.6
-
-
Remák, E.1
Brown, R.2
Négrier, S.3
Motzer, R.J.4
Kim, S.T.5
Charbonneau, C.6
-
21
-
-
44349126126
-
Economic evaluations of sunitinib versus interferon-A (IFN-α) in first-line metastatic renal cell carcinoma (mRCC
-
(Abstract 6607
-
Remαk E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K. Economic evaluations of sunitinib versus interferon-a (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25(Suppl. 18S) (2007) (Abstract 6607).
-
(2007)
J. Clin. Oncol
, vol.25
, Issue.SUPPL. 18
-
-
Remák, E.1
Mullins, C.D.2
Akobundu, E.3
Charbonneau, C.4
Woodruff, K.5
-
22
-
-
80051774942
-
Economic implications of the first line treatment of advanced renal cell carcinoma in Thailand: A cost-effectiveness analysis
-
Phuket, Thailand, 5-7 September
-
Topibulpong N, Tanasanvimon S, Parinyanitikul N, Vinayanuwattikun C, Sriuranpong V. economic implications of the first line treatment of advanced renal cell carcinoma in Thailand: a cost-effectiveness analysis. Presentedt at: ISPOR 4th Asia-Pacific Conference. Phuket, Thailand, 5-7 September 2010.
-
(2010)
ISPOR 4th Asia-Pacific Conference
-
-
Topibulpong, N.1
Tanasanvimon, S.2
Parinyanitikul, N.3
Vinayanuwattikun, C.4
Sriuranpong, V.5
-
23
-
-
84857107569
-
Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
-
Abstract 17556
-
Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S. Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States. J. Clin. Oncol. 27 (2009) (Abstract 17556).
-
(2009)
J. Clin. Oncol.
, vol.27
-
-
Benedict, A.1
Figlin, R.A.2
Charbonneau, C.3
Kreif, N.4
Hariharan, S.5
Négrier, S.6
-
24
-
-
84857102175
-
Cost effectiveness analysis of sunitinib, bevacizumab plus interferon-A and temsirolimus as first-line therapy of metastatic renal cell carcinoma in Sweden
-
Remák E, Vioix H, Sandin R, Harmenberg U, Ullen A, Sandstom P. Cost effectiveness analysis of sunitinib, bevacizumab plus interferon-a and temsirolimus as first-line therapy of metastatic renal cell carcinoma in Sweden. Value Health 12(7), A270 (2009).
-
(2009)
Value Health
, vol.12
, Issue.7
-
-
Remák, E.1
Vioix, H.2
Sandin, R.3
Harmenberg, U.4
Ullen, A.5
Sandstom, P.6
-
25
-
-
80051720645
-
Cost-effectiveness analysis of temsirolimus vs. sunitinib malate in poor prognosis metastatic renal cell carcinoma (mRCC) in Portugal
-
Silverio NM, Yang S, Alemao E. Cost-effectiveness analysis of temsirolimus vs. sunitinib malate in poor prognosis metastatic renal cell carcinoma (mRCC) in Portugal. Value Health 12(7), A271 (2009).
-
(2009)
Value Health
, vol.12
, Issue.7
-
-
Silverio, N.M.1
Yang, S.2
Alemao, E.3
-
26
-
-
77954522229
-
Cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: Perspective of the Spanish National Health System
-
Paz-Ares L, del Muro JG, Grande E, Díaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J. Clin. Pharm. Ther. 35(4), 429-438 (2010).
-
(2010)
J. Clin. Pharm. Ther
, vol.35
, Issue.4
, pp. 429-438
-
-
Paz-Ares, L.1
Del Muro, J.G.2
Grande, E.3
Díaz, S.4
-
27
-
-
41549092232
-
Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
-
DOI 10.1016/j.clinthera.2008.02.013, PII S0149291808000969
-
Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu- Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin. Ther. 30(2), 382-392 (2008). (Pubitemid 351474383)
-
(2008)
Clinical Therapeutics
, vol.30
, Issue.2
, pp. 382-392
-
-
Purmonen, T.1
Martikainen, J.A.2
Soini, E.J.O.3
Kataja, V.4
Vuorinen, R.-L.5
Kellokumpu-Lehtinen, P.-L.6
-
28
-
-
84857101842
-
A cost-utility analysis model for the second line treatment of metastatic renal cell carcinoma in Mexico
-
Garduño-Espinosa J, Contreras- Hernandez I, Mould-Quevedo J, Salinas-Escudero G, Tapia-Valencia J, Davila-Loaiza G. A cost-utility analysis model for the second line treatment of metastatic renal cell carcinoma in Mexico. Value Health 10(3), A132-A133 (2007).
-
(2007)
Value Health
, vol.10
, Issue.3
-
-
Garduño-Espinosa, J.1
Contreras-Hernandez, I.2
Mould-Quevedo, J.3
Salinas-Escudero, G.4
Tapia-Valencia, J.5
Davila-Loaiza, G.6
-
29
-
-
77954471321
-
Sunitinib malate provides additional survival and value for money as a second line treatment for metastatic renal cell carcinoma (mRCC) - An economic evaluation using Bayesian approach
-
Purmonen T, Martikainen JA, Soini EJ, Kataja V, Kellokumpu-Lehtinen PL. Sunitinib malate provides additional survival and value for money as a second line treatment for metastatic renal cell carcinoma (mRCC) - an economic evaluation using Bayesian approach. Value Health 10(6), A337 (2007).
-
(2007)
Value Health
, vol.10
, Issue.6
-
-
Purmonen, T.1
Martikainen, J.A.2
Soini, E.J.3
Kataja, V.4
Kellokumpu-Lehtinen, P.L.5
-
30
-
-
77954473386
-
Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium
-
van Nooten F, Dewilde S, Van Belle S, Marbaix S. Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium. Value Health 10(6), A329 (2007).
-
(2007)
Value Health
, vol.10
, Issue.6
-
-
Van Nooten, F.1
Dewilde, S.2
Van Belle, S.3
Marbaix, S.4
-
31
-
-
79952687479
-
Economic burden of renal cell carcinoma: Part i - An updated review
-
Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: part I - an updated review. Pharmacoeconomics 29(4), 315-329 (2011).
-
(2011)
Pharmacoeconomics
, vol.29
, Issue.4
, pp. 315-329
-
-
Shih, Y.C.1
Chien, C.R.2
Xu, Y.3
Pan, I.W.4
Smith, G.L.5
Buchholz, T.A.6
-
34
-
-
77954484245
-
Current and predicted cost of metastatic renal cell carcinoma in Finland
-
Purmonen T, Nuttunen P, Vuorinen R, Pyrhönen S, Kataja V, Kellokumpu-Lehtinen P. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta. Oncol. 49(6), 837-843 (2010).
-
(2010)
Acta. Oncol
, vol.49
, Issue.6
, pp. 837-843
-
-
Purmonen, T.1
Nuttunen, P.2
Vuorinen, R.3
Pyrhönen, S.4
Kataja, V.5
Kellokumpu-Lehtinen, P.6
-
35
-
-
76949102287
-
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-A in a Phase III trial: Final results and geographical analysis
-
Cella D, Michaelson MD, Bushmakin AG et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a Phase III trial: final results and geographical analysis. Br. J. Cancer 102(4), 658-664 (2010).
-
(2010)
Br. J. Cancer
, vol.102
, Issue.4
, pp. 658-664
-
-
Cella, D.1
Michaelson, M.D.2
Bushmakin, A.G.3
-
36
-
-
74249091926
-
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-A2a compared with sunitinib
-
Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-a2a compared with sunitinib. Br. J. Cancer 102(1), 80-86 (2010)
-
(2010)
Br. J. Cancer
, vol.102
, Issue.1
, pp. 80-86
-
-
Mickisch, G.1
Gore, M.2
Escudier, B.3
Procopio, G.4
Walzer, S.5
Nuijten, M.6
-
37
-
-
79952917182
-
Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
-
Mickisch GH, Schwander B, Escudier B et al. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon. Outcomes Res. 3, 19-27 (2011).
-
(2011)
Clinicoecon. Outcomes Res.
, vol.3
, pp. 19-27
-
-
Mickisch, G.H.1
Schwander, B.2
Escudier, B.3
-
38
-
-
60549104635
-
Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
-
Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 9(34) (2009).
-
(2009)
BMC Cancer
, vol.9
, pp. 34
-
-
Mills, E.J.1
Rachlis, B.2
O'Regan, C.3
Thabane, L.4
Perri, D.5
-
39
-
-
60849132105
-
Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon-A or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison
-
Abstract 5048
-
Benedict A, Charbonneau C, Hidi J, Kim ST, Négrier S. Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon-a or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): an indirect comparison. J. Clin. Oncol. 26, (2008) (Abstract 5048).
-
(2008)
J. Clin. Oncol.
, vol.26
-
-
Benedict, A.1
Charbonneau, C.2
Hidi, J.3
Kim, S.T.4
Négrier, S.5
-
40
-
-
84857102720
-
Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-A (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) - An indirect comparison
-
Benedict A, Charbonneau C, Kim ST, Négrier S. Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-a (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) - an indirect comparison. Ann. Oncol. 19(Suppl. 8), 227 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, Issue.SUPPL. 8
, pp. 227
-
-
Benedict, A.1
Charbonneau, C.2
Kim, S.T.3
Négrier, S.4
-
41
-
-
80051745686
-
Economic evaluation of sunitinib first-line for metastatic renal cell carcinoma versus sorafenib, temsirolimus and bevacizumab plus interferon-A in the Swedish health service setting
-
Sandin R, Munir U, Benedict A et al. economic evaluation of sunitinib first-line for metastatic renal cell carcinoma versus sorafenib, temsirolimus and bevacizumab plus interferon-a in the Swedish health service setting. Value Health 11(6), A468 (2008).
-
(2008)
Value Health
, vol.11
, Issue.6
-
-
Sandin, R.1
Munir, U.2
Benedict, A.3
-
42
-
-
80051749582
-
Cost-effectiveness of sunitinib (SU) vs sorafenib (SFN), temsirolimus (TMS) and bevacizumab plus interferon-A (BEV/IFN) as first-line therapy for metastatic renal cell carcinoma (mRCC) - Adaptation for the Swedish health service
-
Munir U, Benedict A, Borgman B et al. Cost-effectiveness of sunitinib (SU) vs sorafenib (SFN), temsirolimus (TMS) and bevacizumab plus interferon-a (BEV/IFN) as first-line therapy for metastatic renal cell carcinoma (mRCC) - adaptation for the Swedish health service. Ann. Oncol. 19(Suppl. 8), 228 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, Issue.SUPPL. 8
, pp. 228
-
-
Munir, U.1
Benedict, A.2
Borgman, B.3
-
43
-
-
77958008740
-
Cost-effectiveness (CE) evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Abstract 409
-
San Francisco, CA, USA, 5-7 March
-
Calvo E, Maroto-Rey P, Gonzalez- Larriba JL et al. Cost-effectiveness (CE) evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Abstract 409. Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010.
-
(2010)
ASCO Genitourinary Cancers Symposium
-
-
Calvo, E.1
Maroto-Rey, P.2
Gonzalez-Larriba, J.L.3
-
44
-
-
80051744913
-
Cost-effectiveness and cost-utility analysis of sunitinib (SU) vs sorafenib (SFN) and bevacizumab plus interferon-A (BEV/IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain
-
Diaz S, Calvo E, Maroto P, Puente J, Lopez- Brea M, Castellano D. Cost-effectiveness and cost-utility analysis of sunitinib (SU) vs sorafenib (SFN) and bevacizumab plus interferon-a (BEV/IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Ann. Oncol. 19(Suppl. 8), 227 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, Issue.SUPPL. 8
, pp. 227
-
-
Diaz, S.1
Calvo, E.2
Maroto, P.3
Puente, J.4
Lopez- Brea, M.5
Castellano, D.6
-
45
-
-
84857101518
-
Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study)
-
Rio de Janeiro, Brazil 10-12 September
-
Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study). Presented at: ISPOR 2 Latin America Conference, Rio de Janeiro, Brazil, 10-12 September 2009.
-
(2009)
ISPOR 2 Latin America Conference
-
-
Godoy, J.I.1
Cardona, A.F.2
Cáceres, H.3
-
46
-
-
77950797255
-
Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study
-
Abstract 16150
-
Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 16150).
-
(2009)
J. Clin. Oncol
, vol.27
, Issue.SUPPL. 15
-
-
Godoy, J.I.1
Cardona, A.F.2
Cáceres, H.3
-
47
-
-
84857107071
-
Economic evaluation of sunitinib vs. interferon-A (IFN-a) in first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia
-
Cáceres H, Godoy JI, Cardona AF et al. Economic evaluation of sunitinib vs. interferon-a (IFN-a) in first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia. Value Health 11(3), A100 (2008).
-
(2008)
Value Health
, vol.11
, Issue.3
-
-
Cáceres, H.1
Godoy, J.I.2
Cardona, A.F.3
-
48
-
-
80051729677
-
Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab plus interferon-A as first-line treatment for metastatic renal cell carcinoma in Mexico
-
Salinas-Escudero G, Contreras- Hernandez I, Mould-Quevedo J. Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab plus interferon-a as first-line treatment for metastatic renal cell carcinoma in Mexico. Value Health 12(7), A497 (2009).
-
(2009)
Value Health
, vol.12
, Issue.7
-
-
Salinas-Escudero, G.1
Contreras-Hernandez, I.2
Mould-Quevedo, J.3
-
49
-
-
80051736063
-
Pharmacoeconomic evaluation of sunitinib malate for first-line treatment of metastatic renal cell carcinoma in Mexico
-
Orlando, FL, USA 18 May
-
Mould-Quevedo J, Tenorio C, Vargas J et al. Pharmacoeconomic evaluation of sunitinib malate for first-line treatment of metastatic renal cell carcinoma in Mexico. Presented at: ISPOR 14th Annual International Meeting. Orlando, FL, USA, 18 May 2009.
-
(2009)
ISPOR 14th Annual International Meeting
-
-
Mould-Quevedo, J.1
Tenorio, C.2
Vargas, J.3
-
50
-
-
80051773070
-
Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon a and temsirolimus in first line treatment of metastatic renal cell carcinoma in Israel
-
Greenberg D. Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon a and temsirolimus in first line treatment of metastatic renal cell carcinoma in Israel. Value Health 12(3), A42 (2009).
-
(2009)
Value Health
, vol.12
, Issue.3
-
-
Greenberg, D.1
-
51
-
-
80051771661
-
Economic evaluation of sunitinib vs. interferon-A and bevacizumab plus interferon-A in the treatment of metastatic renal cell carcinoma (ccrm) - Brazilian private health system perspective
-
Teich V, Hashizume CM, Marinho T, Charbonneau C, Naves A. Economic evaluation of sunitinib vs. interferon-a and bevacizumab plus interferon-a in the treatment of metastatic renal cell carcinoma (ccrm) - Brazilian private health system perspective. Value Health 13(3), A37 (2010).
-
(2010)
Value Health
, vol.13
, Issue.3
-
-
Teich, V.1
Hashizume, C.M.2
Marinho, T.3
Charbonneau, C.4
Naves, A.5
-
52
-
-
75349093467
-
Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina
-
Aiello EC, Muszbek N, Richardet E, Lingua A, Charbonneau C, Remák E. Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina. Value Health 10(3), A127-A128 (2007
-
(2007)
Value Health
, vol.10
, Issue.3
-
-
Aiello, E.C.1
Muszbek, N.2
Richardet, E.3
Lingua, A.4
Charbonneau, C.5
Remák, E.6
|